Scilex Holding (SCLXW) Assets Average (2021 - 2026)
Scilex Holding (SCLXW) recorded quarterly Assets Average of $329.3 million in Q1 2026, up 2.77% quarter-over-quarter from $320.4 million in Q4 2025, and up 283.07% on a YoY basis from $86.0 million in Q1 2025.
Scilex Holding (SCLXW) Assets Average (2021 - 2026) Analysis & Trends
Scilex Holding's Assets Average history runs 6 years deep, the most recent figure standing at $329.3 million for Q1 2026.
- In Q1 2026, Assets Average rose 283.07% year-over-year to $329.3 million; the TTM figure through Mar 2026 stood at $329.3 million (up 283.07% YoY), while the FY2025 annual figure was $229.0 million, up 135.73% from the prior year.
- Assets Average was $329.3 million for Q1 2026 at Scilex Holding, up from $320.4 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $329.3 million in Q1 2026 to a low of $81.4 million in Q2 2025.
- Historically, Assets Average has averaged $132.0 million across 5 years, with a median of $102.5 million in 2024.
- The sharpest annual moves came in 2023 and 2026: Assets Average fell 24.98% in 2023, then jumped 283.07% in 2026.
- A 5-year view of Assets Average shows it stood at $94.0 million in 2022, then fell by 3.27% to $90.9 million in 2023, then increased by 6.35% to $96.7 million in 2024, then surged by 231.39% to $320.4 million in 2025, then grew by 2.77% to $329.3 million in 2026.
- The last three Assets Average figures came in at $329.3 million (Q1 2026), $320.4 million (Q4 2025), and $179.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 83.03 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 114.53 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 200.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 135.21 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 88.26 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 329.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 329.31 Mn |
| Dec 31, 2025 | 320.43 Mn |
| Sep 30, 2025 | 179.82 Mn |
| Jun 30, 2025 | 81.37 Mn |
| Mar 31, 2025 | 85.96 Mn |
| Dec 31, 2024 | 96.69 Mn |
| Sep 30, 2024 | 102.49 Mn |
| Jun 30, 2024 | 97.89 Mn |
| Mar 31, 2024 | 96.27 Mn |
| Dec 31, 2023 | 90.92 Mn |
| Sep 30, 2023 | 103.50 Mn |
| Jun 30, 2023 | 106.26 Mn |
| Mar 31, 2023 | 86.29 Mn |
| Dec 31, 2022 | 93.99 Mn |
| Sep 30, 2022 | 121.88 Mn |
| Jun 30, 2022 | 141.64 Mn |
| Mar 31, 2022 | 109.45 Mn |
| Dec 31, 2021 | 108.79 Mn |
| Sep 30, 2021 | 139.77 Mn |
| Jun 30, 2021 | 139.98 Mn |